NewsPronto

 
Times Advertising


.

ACN Newswire

Read more press releases from ACN Newswire here

China Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter

  • Written by ACN Newswire
HONG KONG, Jan 28, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao") received an approval letter from the National Medical Products Administration for a clinical trial of the Company's LY007...

Read more: China Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter